aggrego Conference Hub

Carefully curated news articles, video interviews, and podcasts providing live, in-depth coverage of oncology meetings, conferences, and congresses within the United States and abroad.
Conference Calendar
ASCO Annual Meeting
More
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The ASCO Post
Tazemetostat Plus Lenalidomide and Rituximab Shows Promising Safety, Efficacy for Relapsed/Refractory FL
Oncology Learning Network
High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Cancer Therapy Advisor
Study Shows Which Patients With Advanced Prostate Cancer Will Benefit From Chemotherapy
Medical Xpress
Endocrine Therapy Predominant Therapeutic Option in HR+/HER2-Negative Advanced Breast Cancer
Oncology Learning Network
Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation
Oncology Nurse Advisor
MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma
The ASCO Post
Acupuncture Improves Symptoms of Radiation-Induced Xerostomia in Head and Neck Cancer
Cancer Therapy Advisor
Findings From a Prospective Phase II Study With Dostarlimab for Advanced Local Rectal Cancer
Medical Xpress
ESMO Congress
More
Jaktinib Improves Clinical Symptoms in JAK Inhibitor-Naïve Patients With Myelofibrosis
Oncology Learning Network
Can New Routes of Administration Have a Place in the Application of Immunotherapy?
ESMO Daily Reporter
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis and Low Platelet Count (50 × 109/L to <100 × 109/L) at Baseline: The Final Analysis of EXPAND
Therapeutic Advances in Hematology
The Effect of ‘Publish or Perish’ on Young Academic Oncologists
ESMO Daily Reporter
Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer
MedPage Today
Nirogacestat for Progressive Desmoid Tumors: DeFi Trial
The ASCO Post
European Cancer Prevention Initiative Launched at ESMO Congress
Medscape
Predictors of Thrombosis and Bleeding in 1613 Myelofibrosis Patients From the Spanish Registry of Myelofibrosis
British Journal of Haematology
Abstract 7 Reduced Intensity Conditioning Umbilical Cord Blood Transplantation in Combination With Splenic Irradiation in a Patient With Secondary Myelofibrosis and Massive Splenomegaly
Stem Cells Translational Medicine
SOHO Annual Meeting
More
High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
Hemasphere
The Third Dose of mRNA SARS-CoV-2 Vaccines Enhances the Spike-Specific Antibody and Memory B Cell Response in Myelofibrosis Patients
Frontiers in Immunology
2-Year Nonrecurrence Linked With Improved Long-Term Survival With Haplo-SCT
Hematology Advisor
Though Improved, Outcomes Remain Poor for Patients With MDS Who Progress on HMA Therapy
Cancer Therapy Advisor
MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study
ScienceDirect
CLO22-065: Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach
JNCCN
Venetoclax Plus Azacitidine Appears Promising in High-Risk MDS, CMML
Cancer Therapy Advisor
Incidence and Predictors of Thrombotic Events in Secondary Myelofibrosis
Hematology Advisor
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation With Omidubicel Versus Umbilical Cord Blood
ScienceDirect
MPN Congress
More
Germline-Somatic Interactions, Telomere Biology Affect Myelofibrosis Risk
NIH DCEG News Updates
New Platform Matches Patients to Precision Oncology Trials
Hematology Advisor
Improvement in Primary Autoimmune Myelofibrosis Following a Short Course of Steroids and Intravenous Immunoglobulins
Cureus
Navitoclax Plus Ruxolitinib in JAK Inhibitor-Naive Patients With Myelofibrosis: Preliminary Safety and Efficacy in a Multicenter, Open-Label Phase 2 Study
Journal of Clinical Oncology
Single Gene Analysis Deciphers Protein Role in Regulation of ECM Genes in MPNs
Blood Cancers Today
Endoscopic Procedures Improve Gastroesophageal Variceal Rebleeding in MPN
Hematology Advisor
Use of Life Expectancy as a Criterion to Discontinue Cancer Screenings
Oncology Nurse Advisor
Momelotinib Demonstrated Superior Responses, Survival to Danazol in Patients With Thrombocytopenic Myelofibrosis
Oncology Learning Network
Study Advances Knowledge Base About Children, Young Adults With MPNs
Cancer Therapy Advisor
ASH Annual Meeting & Exposition
More
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
The ASCO Post
Report from the 2022 American Society of Hematology Annual Meeting — Malignant Hematology
NEJM
ASH 2022: MCL Trials Break New Ground, May Change Practice
Cancer Therapy Advisor
Breaking Down Geographical Barriers for Adolescents and Young Adults Receiving ALL Care
Aggrego Oncology
How IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
Aggrego Oncology
Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers
Aggrego Oncology
Comparing 1-Year OS and RFS in Patients Treated With ABA in Combination With a CNI/MTX vs ATG or PT-Cy Following Allogenic HCT
Aggrego Oncology
Clinical Outcomes, Correlative Efficacy Analyses in Patients With R/R FL Treated With Tisagenlecleucel in the Elara Trial
Aggrego Oncology
Hemostatic Biomarkers Predict Risk of TE, Severe COVID-19, and Mortality: The NCCAPS Study
Aggrego Oncology
SABCS 2022
More
Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03, A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
Journal of Clinical Pathways
Worse Breast Cancer Outcomes for Black Women Tempered by BMI
Medscape
General Session 3 Includes Latest Results From SERENA-2, Capitello–291, and STIC CTC Trials
SABCS Meeting News
Capivasertib Improves PFS in AI-Resistant, HR+/HER2– Advanced Breast Cancer
Cancer Therapy Advisor
Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer
The ASCO Post
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented at 2022 SABCS
Bakersfield.com
Astrazeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum at SABCS 2022
AstraZeneca
Special ‘C. Kent Osborne Symposium’ to Focus on HER2, ER Crosstalk
SABCS Meeting News
ASCO Gastrointestinal Cancers Symposium
More
VIDEO: NALIRIFOX Versus Nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC
Aggrego Oncology
VIDEO: Zolbetuximab Plus mFOLFOX6 Improves Survival in Gastric/Gastroesophageal Junction Adenocarcinoma
Aggrego Oncology
ASCO GI Recap: Groundbreaking Studies and Exciting Developments in Gastrointestinal Cancers
Aggrego Oncology
Nivolumab Plus Chemotherapy or Ipilimumab vs Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma
Aggrego Oncology
NALIRIFOX Significantly Improves OS and PFS in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Aggrego Oncology
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Patients With Metastatic CRC: SUNLIGHT Study
Aggrego Oncology
Regorafenib Prolongs OS vs Placebo in Patients With Advanced Gastroesophageal Cancer
Aggrego Oncology
Zolbetuximab Plus mFOLFOX6 Improves Survival in Gastric/Gastroesophageal Junction Adenocarcinoma
Aggrego Oncology
Procedural Volume May Impact Outcomes of Endoscopic Submucosal Dissection
Cancer Therapy Advisor